During the first six months of Maziar Mike Doustdar's tenure as Novo Nordisk's CEO, the company enjoyed a run of positive ...

Ahead of the readouts, BMS and J&J have started an educational push called “Change the Target. Change What’s Possible,” they ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s ...

AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. | AstraZeneca will have to negotiate what ...

Over the last decade-plus, China has become a booming biopharma innovator thanks in part to a big boost from its government. Now the question is, can its neighbor to the south, India, make a similar ...

With Valentine’s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new ...

The FDA laid out the qualifications a site would need to qualify for PreCheck on a webpage where companies can also submit ...

Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck ...

On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley, rounding ...

For teams navigating an AI-driven future, this conversation offers practical clarity. Listen to the full interview to learn ...

Earlier this month at the J.P. Morgan Healthcare Conference, Regeneron got its Eylea sales news out of the way. | For the ...